Humate-P Dosing Calculator for von Willebrand Disease
Dosing Calculator (Application)
The Humate-P dosing calculator is here, making individual dosing
fast, easy and convenient. CSL Behring provides healthcare providers (HCPs) with
yet another innovative tool to improve patient care. This dosing calculator application
makes accurate dosing of Humate-P even more convenient by allowing HCPs to calculate
the dosing needed for patients with von Willebrand disease. The application
can calculate dosages for a variety of patient needs, including emergency surgery,
perioperative and postoperative surgery, and for bleeding episodes.
Available for download
The dosing calculator can be downloaded to your iPhone®, iPad®, or Android. Just click the appropriate link below:
To download the latest Humate-P dosage calculator, copy the following link into
the web browser of your BlackBerry device:
Surgery Dosing Calculator
This unique Humate-P Surgery Dosing Calculator makes individual dosing fast, easy,
and convenient. The calculator determines the correct Humate-P loading dose
(measured in VWF:RCo units) needed to achieve the desired increase in circulating
VWF, as defined in the product prescribing information. (For guidance on loading
dose recommendations, please refer to Table 3 of the
full prescribing Information). All subsequent doses should be based on patient
response and measured levels of VWF:RCo and FVIII.
These calculations are to be used only with Humate-P and are applicable for VWF:RCo
loading dose calculations for the prevention of excessive bleeding during and after
surgery for all types of VWD.
Calculator for Loading Dose for Humate-P
Instructions: To determine the Humate-P loading dose (as measured in VWF:RCo
units) needed to achieve the target increase in circulating VWF:
- Enter the patient's body weight (BW) in kilograms (kg) OR pounds (lb)
- Enter the patient's baseline level (BL) of VWF:RCo (measured as IU VWF:RCo/dL)
- Enter the patient's target level (TL) of VWF:RCo (measured as IU VWF:RCo/dL)
- Enter the patient's in vivo recovery (IVR). IVR is measured as rise in IU/dL per
IU/kg administered. If unknown, please click on the link next to the IVR field and
a value of 2 IU/dL will be used as the default per the dosage instructions in the
product prescribing information.
Based on the following formula, your patient's Humate-P dose is
A full chart of the Humate-P Surgery
Dosing Calculator for VWD is also available. General Rule: Doses are calculated
based on an expected in vivo recovery of 2.0 IU/dL rise in VWF:RCo activity per
every IU/kg of VWF:RCo administered.
iPhone and iPad are registered trademarks of Apple, Inc.
BlackBerry is a registered trademark of Research In Motion Limited.
Important Safety Information
Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.
Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.
Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.
Thromboembolic events have been reported in VWD patients receiving coagulation
factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with risk factors for thrombosis.
Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions (reported by >5% of subjects) were allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, and edema. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.